Daniel S. Lorrain insider trades

Open-market stock purchases and sales by Daniel S. Lorrain, Chief Scientific Officer at Contineum Therapeutics, Inc, from SEC Form 4 filings since May 24, 2024.

Recent trades

DateStockTradeValue
Jun 1, 2026CTNM Contineum Therapeutics, IncSold$54.9K
May 1, 2026CTNM Contineum Therapeutics, IncSold$50.5K
May 1, 2026CTNM Contineum Therapeutics, IncSold$4.2K
Apr 6, 2026CTNM Contineum Therapeutics, IncSold$56K
Mar 2, 2026CTNM Contineum Therapeutics, IncSold$62.6K
Feb 25, 2026CTNM Contineum Therapeutics, IncSold$61.2K
Feb 25, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Feb 24, 2026CTNM Contineum Therapeutics, IncSold$68.9K
Feb 24, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Feb 19, 2026CTNM Contineum Therapeutics, IncSold$1.6K
Feb 19, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Feb 11, 2026CTNM Contineum Therapeutics, IncSold$6.4K
Feb 11, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Feb 3, 2026CTNM Contineum Therapeutics, IncSold$44.5K
Feb 3, 2026CTNM Contineum Therapeutics, IncSold$17.8K
Jan 30, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Jan 30, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Jan 5, 2026CTNM Contineum Therapeutics, IncSold$38K
Jan 5, 2026CTNM Contineum Therapeutics, IncSold$5.6K
Dec 23, 2025CTNM Contineum Therapeutics, IncSold$51K

Companies traded

  • CTNM Contineum Therapeutics, Inc: 17 sales, last Jun 1, 2026

Get free alerts when Daniel S. Lorrain files a new trade →